Leniolisib NEW
| Price | $72 | $156 | $235 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Leniolisib | CAS No.: 1354690-24-6 |
| Purity: 99.97% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Leniolisib |
| Description | Leniolisib (CDZ173) (CDZ173) is a potent and selective PI3Kδ inhibitor (IC50: 11 nM). |
| Cell Research | Studies in transfected Rat-1 fibroblasts and in primary immune cells isolated from patients with APDS were done to assess the in vitro potency of leniolisib on endogenously activated PI3Kδ. PIK3CD mutants encoding published forms of p110δ variants were generated by site-directed mutagenesis using human PIK3CD complementary DNA and transiently transfected in mammalian Rat-1 fibroblasts. The effects of leniolisib and mTOR inhibition on endogenous PI3K/AKT pathway activity in the transfectants were evaluated by measuring phosphorylated AKT (pAKT; S473) using homogeneous time-resolved fluorescence. T-cell blasts from healthy donors as well as APDS patients were generated from isolated T cells by stimulation with anti-CD3 and anti-CD28 antibodies for 3 days. Cells were then incubated with titrated amounts of leniolisib, stimulated with anti-CD3, and the phosphorylation of AKT(S473) and S6(S240/244) was determined by flow cytometry [2]. |
| Animal Research | Female wild-type Sprague Dawley rats were kept in standard cages and conditions according to Swiss Animal Welfare guidelines (12h light/dark cycles, RT at 22-24 °C, humidity at least 45 % but <70 %) with free access to Ringer solution (glucose 5%, NaCl 0.9% and KCl 0.5%) and pelleted rodent chow. 96-120 hours before administration of the test substance the animals were anesthetized with isoflurane and catheters were surgically implanted under aseptic precautions (use of sterile instruments and surgical material in combination with local antibiotic prophylaxis) into the femoral artery and vein. The catheters were exteriorized in the neck region, connected to a Harvard swivel system and filled with 0.9% saline containing 100 U/mL heparin. After recovery from anesthesia, the animals were housed individually in special cages with free access to food and tap water until and throughout the experiment. Analgesic treatment with Temgesic (10 μg/kg s.c., application volume 1 mL/kg) was performed in the evening following surgery and in the next morning. Compound administration was in the morning (6-8 AM). Blood samples were collected at various time points from the femoral artery catheter into Eppendorf tubes coated with sodium EDTA. Blood samples were immediately frozen at –20 °C until final processing (maximum storage was 8 days). Intravenous and oral dosing was performed in the same animals after a 48 h wash-out interval between the single dose applications. The test substance was administered intravenously as a solution in 1-methyl-2-pyrrolidone and polyethylene glycol 200 (30:70, v/v) at a dose of 1 mg/kg and orally as a homogenous aqueous suspension in Tween 80 and carboxymethyl cellulose sodium 0.5/0.5/99 (w/w) at a dose of 3 mg/kg [1]. |
| In vitro | Leniolisib (CDZ173) inhibits a large spectrum of immune cell functions, as demonstrated in B and T cells, neutrophils, monocytes, basophils, plasmocytoid dendritic cells, and mast cells [1]. Treatment with CDZ173 caused dose-dependent suppression of PI3Kδ pathway hyperactivation (measured as phosphorylation of AKT/S6) in cell lines ectopically expressing APDS-causative p110δ variants and in T-cell blasts derived from patients [2]. |
| In vivo | In vivo, CDZ173 inhibits B cell activation in rats and monkeys in a concentration- and time-dependent manner. After prophylactic or therapeutic dosing, CDZ173 potently inhibited antigen-specific antibody production and reduced disease symptoms in a rat collagen-induced arthritis model [1]. Oral leniolisib led to a dose-dependent reduction in PI3K/AKT pathway activity assessed ex vivo and improved immune dysregulation. After 12 weeks of treatment, all patients showed amelioration of lymphoproliferation with lymph node sizes and spleen volumes reduced by 39% and 40%, respectively [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 10 mg/mL (22.2 mM), Sonication is recommended. DMSO : 16.67 mg/mL (37.01 mM), Sonication is recommended. H2O : Insoluble 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.44 mM), Sonication is recommended. |
| Keywords | PI3Kδ | PI3K | Phosphoinositide 3-kinase | Leniolisib | Inhibitor | inhibit | DNA-PK | DNAPK | CDZ-173 | CDZ 173 |
| Inhibitors Related | Musk ketone | Myricetin | Creatine monohydrate | Hyaluronic acid | 4-Methylbenzylidene camphor | 4-Vinylcyclohexene Dioxide | Berberine hydrogen sulphate | Isoprenaline hydrochloride | Quercitrin hydrate | Methyl eugenol | Quercetin | Berberine sulfate |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | ||
| $9.90 |
Wuhan Biocar Pharmacy CO.,Ltd.
|
2025-12-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY